From eradicating smallpox to battling the COVID-19 pandemic, these vaccine pioneers have helped make colossal strides in public health.

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...